IMVT Immunovant Inc

Price (delayed)

$34.54

Market cap

$7.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.82

Enterprise value

$6.34B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies ...

Highlights
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter
IMVT's quick ratio is down by 40% year-on-year and by 21% since the previous quarter
IMVT's net income is down by 20% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of IMVT

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-7.37%
1 week
-5.06%
1 month
-22.15%
1 year
131.81%
YTD
35.88%
QTD
-10.36%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$566M
Net income
-$538.22M
Gross margin
N/A
Net margin
N/A
IMVT's net income is down by 20% YoY and by 6% from the previous quarter
The operating income has declined by 20% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does IMVT's price correlate with its fundamentals

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
9.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The stock's price to book (P/B) is 65% more than its 5-year quarterly average of 6.3 and 55% more than its last 4 quarters average of 6.7
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity is up by 18% year-on-year but it is down by 2.1% since the previous quarter
IMVT's return on assets is up by 17% year-on-year

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total liabilities has surged by 121% year-on-year and by 12% since the previous quarter
Immunovant's current ratio has decreased by 41% YoY and by 20% QoQ
Immunovant's debt is 100% lower than its equity
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.